Platinum Resistance

Platinum drug-resistant patients have a genetically advanced form of cancer and are unlikely to benefit from cytotoxic therapy.

Analysis of resistance can provide information to:

• Select patients for inclusion/exclusion into clinical trials
• Retrospectively evaluate differential patient responses
• Customize patient treatment in tumor types where platinum drugs are generally used
• Prioritize potential secondary and tertiary indications
• Aid/guide development of early stage oncology programs

AltheaDx has developed gene expression tests to monitor response to platinum-based drugs, as well as resistance and toxicity:

NCI Marker Set
Genes differentially responsive in resistant and sensitive patients

Public Marker Set
Genes associated with resistance and/or mechanism of action

ADME-Toxicity Set
Genes that predict kidney toxicity, drug inactivation/metabolism